Loading...

SPRO SPERO THERAPEUTICS INC Business Restructuring 8-K Filing

SPR

SPR

SPERO THERAPEUTICS INC

(SPRO)

2023 8-K

Quarterly Results

Product Expansion

Financial Statements

Earnings Report

SEC Investigation

Q3 Earnings Report

Workforce Reduction

Investor Update

Earnings Reports

Amendment to Stock Incentiv...

Annual Meeting Announcement

Financial Results Announcement

Departure of Directors or C...

Presentation Update

Financial Condition

Clinical Trial Announcement

Earnings Reports

Appointment of Esther Rajav...

Amendment to Filing

Stock Incentive Plan Amendment

Earnings Reports

FDA Agreement for Phase 3 C...

Earnings Report

Financial Results Announcement

Appointment of Chief Operat...

Financial Condition

External Links:

Spero Therapeutics announced a Special Protocol Assessment Agreement with the FDA for a Phase 3 clinical trial of Tebipenem HBr, and will receive a $30.0 million development milestone payment from GSK.

AI Assistant

SPERO THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.